HSPB5 Inhibition by NCI-41356 Reduces Experimental Lung Fibrosis by Blocking TGF-β1 Signaling

HSPB5 Inhibition by NCI-41356 Reduces Experimental Lung Fibrosis by Blocking TGF-β1 Signaling

Idiopathic pulmonary fibrosis is a chronic, progressive and lethal disease of unknown etiology that ranks among the most frequent interstitial lung diseases. Idiopathic pulmonary fibrosis is characterized by dysregulated healing mechanisms that lead to the accumulation of large amounts of collagen i...

Full description

Bibliographic Details
Main Authors: Julie Tanguy, Pierre-Marie Boutanquoi, Olivier Burgy, Lucile Dondaine, Guillaume Beltramo, Burhan Uyanik, Carmen Garrido, Philippe Bonniaud, Pierre-Simon Bellaye, Françoise Goirand
Format: Article
Language:English
Published: MDPI AG 2023-01-01
Series:Pharmaceuticals
Subjects:
TGF-β
HSPB5
pulmonary fibrosis (PF)
anti-fibrotic therapy
Online Access:https://www.mdpi.com/1424-8247/16/2/177

Internet

https://www.mdpi.com/1424-8247/16/2/177

Similar Items